Cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide, affecting millions of lives while driving substantial medical costs and resource...
Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics...
Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention,...
Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence, has engaged IBN to support its corporate communications...
Cardio Diagnostics Holdings (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management...
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence...
Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.
Southdale YMCA, part of YMCA of the North, becomes the second YMCA location nationally to partner with Cardio Diagnostics, expanding community access to AI-powered cardiovascular testing and education
The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™....
Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are two underdiagnosed, potentially fatal forms of heart disease that standard...